Overview
FATE market data
Business OverviewA provider-written description of this company or fund, with its source and observation date.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
- Source
- massive
- Observed
- Cadence
- Reference data reviewed periodically
- Status
- fresh
No longer tradingThis symbol is retired in our registry: it no longer trades, so it has no live decision and cannot be traded here.
- Last Close
- $1.85
- Last Trading Day
- 2026-11-06
Price HistoryDaily closing prices from recorded market data. The latest point represents the most recent completed daily period; prices can move before the next point appears.
FATE price chart · 1M
- O
- 1.86
- H
- 1.92
- L
- 1.81
- C
- 1.85
- Vol
- 56,522.00
Daily history from Jan 12, 2026
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- stale
Key Stats & PerformanceOpen, range, return and notional-volume facts calculated from daily market bars.
- Open
- $1.86
- Previous Close
- $1.86
- Day High
- $1.92
- Day Low
- $1.81
- 52 Week High
- $3.23
- 52 Week Low
- $1.02
- 7 Day Return
- -11.51%
- 30 Day Return
- -14.39%
- 90 Day Return
- -33.03%
- 1 Year Return
- —
- Daily Notional Volume
- $104.3K Latest daily bar volume multiplied by its closing price.
Valuation & ProfitabilityProvider-backed valuation, profitability, and range metrics for the selected company. Display-only; never feeds scores or decisions.
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.15 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.68 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -1,941.1% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.95 – $3.23 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $244.4M · P/B 0.55 · P/S 37.66.
Company NewsRecent source-attributed headlines linked to this symbol. Repeated headlines and low-signal items are filtered. Open a headline for its source and context.
10 captured
8-K filing — FATE THERAPEUTICS INC (FATE)SEC EDGAR ·
Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell TherapiesGlobenewswire Inc ·
Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 ConferencesGlobenewswire Inc ·